Wanbury Ltd

Wanbury Management Change

Wanbury Limited announced the appointment of ABK & Associates as Cost Auditor and the re-appointment of Mohan Kumar Rayana as Executive Director.

Wanbury Annual General Meeting

Wanbury Limited held its 38th Annual General Meeting on September 24, 2026. Shareholders approved financial statements, director re-appointments, and cost auditor remuneration ratification.

Wanbury Annual General Meeting

Wanbury Limited has issued a notice for its Annual General Meeting scheduled on September 24, 2026, to transact various business resolutions.

Value

₹0.04 Cr

Wanbury Annual General Meeting

Wanbury Limited has scheduled its 38th Annual General Meeting for September 24, 2026. The meeting will address ordinary business, director re-appointments, and cost auditor remuneration.

Wanbury Product Launch

Wanbury Limited received EDQM approval for Rivaroxaban API. The company also obtained USFDA DMF clearances for Paroxetine HCI and Metformin HCI.

Wanbury Results Update

Wanbury reported Q1 FY27 financial results in a press release. The company also completed a Rs. 205 crore debt refinancing, improving its borrowing profile.

Value

₹205.0 Cr

Wanbury Employee Stock Options

Wanbury Limited allotted equity shares under its Employee Stock Option Plan (ESOP). This issuance increases the company's total paid-up share capital.

Wanbury Management Change

Wanbury Limited has announced the re-appointment of Mr. Mohan Kumar Rayana as an Executive Director, effective August 21, 2026, for a 60-month term.

Wanbury Q1 FY27 Results: Net Profit ₹3.2 Cr, Down 76.3% YoY

Wanbury Ltd reported revenue from operations of ₹165.6 Cr (+1.5% YoY) and net profit of ₹3.2 Cr (-76.3% YoY) for Q1 FY27.

Key figure

Net profit ₹3.2 Cr · -76.3% YoY